Vertex Pharmaceuticals Incorporated
VRTX
$462.13
$5.261.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.76B | 2.91B | 2.77B | 2.65B | 2.69B |
| Total Other Revenue | 10.00M | -- | -- | -- | -- |
| Total Revenue | 2.77B | 2.91B | 2.77B | 2.65B | 2.69B |
| Cost of Revenue | 1.34B | 1.26B | 1.27B | 1.34B | 1.13B |
| Gross Profit | 1.43B | 1.65B | 1.50B | 1.31B | 1.56B |
| SG&A Expenses | 396.40M | 345.00M | 371.80M | 372.20M | 342.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.74B | 1.60B | 1.64B | 1.71B | 1.47B |
| Operating Income | 1.03B | 1.31B | 1.13B | 934.90M | 1.22B |
| Income Before Tax | 730.40M | 1.14B | 1.22B | -3.39B | 1.28B |
| Income Tax Expenses | 84.10M | 223.50M | 178.70M | 202.40M | 179.50M |
| Earnings from Continuing Operations | 646.30M | 913.00M | 1.05B | -3.59B | 1.10B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 646.30M | 913.00M | 1.05B | -3.59B | 1.10B |
| EBIT | 1.03B | 1.31B | 1.13B | 934.90M | 1.22B |
| EBITDA | 1.08B | 1.33B | 1.18B | 988.90M | 1.27B |
| EPS Basic | 2.52 | 3.55 | 4.05 | -13.92 | 4.26 |
| Normalized Basic EPS | 2.79 | 3.44 | 3.00 | 2.59 | 3.29 |
| EPS Diluted | 2.49 | 3.50 | 4.01 | -13.92 | 4.21 |
| Normalized Diluted EPS | 2.76 | 3.40 | 2.96 | 2.59 | 3.25 |
| Average Basic Shares Outstanding | 256.90M | 257.50M | 258.00M | 258.10M | 258.20M |
| Average Diluted Shares Outstanding | 259.50M | 260.50M | 261.00M | 258.10M | 261.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |